| Â | NanoString | TLDA | qPCR |
|---|
miRNA | p | FC | p | FC | p | FC |
|---|
miR-31
|
0.0059
|
-3.9
|
0.0026
|
-10.3
|
0.0040
|
-9.2
|
miR-125b
|
0.0419
|
-2.5
|
0.0066
|
-4.5
|
0.0090
|
-3.6
|
miR-150
|
0.0071
|
-1.9
|
0.0261
|
-1.6
|
0.0003
|
-1.6
|
miR-31*
|
NA
| Â |
0.0043
|
-10.1
|
0.0195
|
-8.5
|
miR-9
|
0.0033
|
1.8
|
0.0489
|
4.1
|
NA
| Â |
miR-181b
|
0.0092
|
1.8
|
NA
| Â |
0.0400
|
1.6
|
miR-29a
|
< 0.1
| Â |
0.0117
|
-1.5
|
0.0180
|
-1.7
|
let-7g
|
0.0004
|
-1.7
|
0.0028
|
-1.5
|
NS
| Â |
miR-16
|
NS
| Â |
0.0061
|
1.5
|
0.0001
|
1.5
|
miR-146b-5p
|
0.0025
|
-2.6
|
0.0020
|
-2.7
|
NS
| Â |
miR-155 | 0.0071 | 1.5 | NS | Â | 0.0690 | 1.3 |
miR-34a | < 0.1 | Â | 0.0514 | 3.6 | 0.0040 | 3.1 |
- For NanoString, TaqMan low-density array (TLDA), and quantitative PCR (qPCR), miRNAs are presented according to the estimated strength of evidence for differential regulation between viremic patients and controls: bold (p < 0.05 for each method with which the respective miRNA was measured); italics (p < 0.05 for two of three); and regular font (p < 0.05 for one platform and p < 0.1 for at least one other). Each of the listed miRNAs had relatively high levels of expression across samples: more than two standard deviations above background (NanoString) and/or amplifying before a threshold cycle of 30 by TaqMan assay. Abbreviations: p = p value; FC = mean fold difference from control (positive or negative as indicated); NS (not significant) refers here to p > 0.1; NA: not measured with the indicated method. miR-150 values for NanoString and TLDA are rendered in bold italics to indicate quantile normalization limitations at expression extremes (miR-150 is one of the most abundant miRNAs in PBMC).
